Human-probability test defeats political donation deductions where banking records mask accommodation-entry fund layering rather than genuine contribu...
Electronic evidence and search statements in tax assessments require authenticity review and corroboration, while procedural manuals lack statutory fo...
Tariff rate quota authorisations govern preferential imports of specified New Zealand goods through export certification and electronic customs debiti...
Electronic Continuity Bond Registration replaces manual container permissions, with quarterly reporting and re-export monitoring for duty-free contain...
Bulk drugs and active pharmaceutical ingredients qualify as "all drugs and medicines" for the specified IGST rate entry because the inclusive statutory definition of "drug" covers substances used as drug components. Their use in manufacture, testing, clinical trials, bioavailability studies or bioequivalence studies does not change their character as drugs. The description-based entry covers APIs even where classified under chemical chapters, and prevails over general chapter-based entries for organic and inorganic chemicals. Imports of bulk drugs or APIs therefore attract IGST at 5% under the relevant rate entry, unless they fall within the separate nil-rated entry.
Bulk drugs and active pharmaceutical ingredients qualify as "all drugs and medicines" for the specified IGST rate entry because the inclusive statutory definition of "drug" covers substances used as drug components. Their use in manufacture, testing, clinical trials, bioavailability studies or bioequivalence studies does not change their character as drugs. The description-based entry covers APIs even where classified under chemical chapters, and prevails over general chapter-based entries for organic and inorganic chemicals. Imports of bulk drugs or APIs therefore attract IGST at 5% under the relevant rate entry, unless they fall within the separate nil-rated entry.
Note: It is a system-generated summary and is for quick reference only.